CRIS Current Research Information System

ZACCHERINI, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.150
NA - Nord America 3.980
EU - Europa 2.863
SA - Sud America 284
AF - Africa 242
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.527
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.905
SG - Singapore 1.287
CN - Cina 1.075
VN - Vietnam 970
IT - Italia 767
GB - Regno Unito 438
SE - Svezia 377
DE - Germania 316
HK - Hong Kong 305
BR - Brasile 191
IN - India 172
NL - Olanda 146
KR - Corea 139
FI - Finlandia 129
FR - Francia 115
RU - Federazione Russa 110
IE - Irlanda 94
CI - Costa d'Avorio 78
TG - Togo 76
CH - Svizzera 71
BG - Bulgaria 69
JO - Giordania 44
AT - Austria 40
JP - Giappone 40
CA - Canada 39
UA - Ucraina 39
AR - Argentina 35
ES - Italia 35
ZA - Sudafrica 35
PL - Polonia 27
MX - Messico 25
ID - Indonesia 24
EE - Estonia 23
EC - Ecuador 20
BE - Belgio 16
IR - Iran 16
BD - Bangladesh 15
SC - Seychelles 14
HR - Croazia 12
IQ - Iraq 11
CL - Cile 10
CO - Colombia 10
NG - Nigeria 10
LT - Lituania 9
PK - Pakistan 9
EG - Egitto 7
CZ - Repubblica Ceca 6
UZ - Uzbekistan 6
VE - Venezuela 6
CD - Congo 5
MY - Malesia 5
PY - Paraguay 5
SA - Arabia Saudita 5
TR - Turchia 5
AE - Emirati Arabi Uniti 4
CR - Costa Rica 4
HU - Ungheria 4
PE - Perù 4
RO - Romania 4
TN - Tunisia 4
AU - Australia 3
KE - Kenya 3
LV - Lettonia 3
MA - Marocco 3
NZ - Nuova Zelanda 3
OM - Oman 3
PH - Filippine 3
RS - Serbia 3
UY - Uruguay 3
AL - Albania 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GR - Grecia 2
KZ - Kazakistan 2
MD - Moldavia 2
NP - Nepal 2
SN - Senegal 2
VA - Santa Sede (Città del Vaticano) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CG - Congo 1
CU - Cuba 1
GA - Gabon 1
IL - Israele 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
LB - Libano 1
MG - Madagascar 1
NI - Nicaragua 1
PA - Panama 1
PR - Porto Rico 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 11.527
Salva come PNG Salva come JPEG
Città #
Singapore 890
Ashburn 543
Southend 357
Dong Ket 340
Fairfield 336
Chandler 324
Hefei 306
Hong Kong 299
Santa Clara 205
Bologna 163
Woodbridge 158
Houston 154
Seoul 139
Wilmington 133
Ho Chi Minh City 130
Beijing 124
Seattle 124
Cambridge 121
Princeton 112
Ann Arbor 105
Boardman 105
Hanoi 103
Helsinki 99
Dublin 92
Dallas 89
Los Angeles 86
Abidjan 78
Lomé 76
Sofia 68
Milan 67
Bern 65
New York 61
Amman 44
Munich 39
Tokyo 37
San Jose 34
Westminster 33
Berlin 32
Redondo Beach 32
Bengaluru 31
Nanjing 31
Frankfurt am Main 28
Jinan 28
Nuremberg 28
Padova 28
San Diego 27
Shenyang 27
Buffalo 25
Rome 25
Turin 25
Guangzhou 23
Florence 22
São Paulo 21
Vienna 21
Zhengzhou 21
London 20
Tianjin 19
Council Bluffs 17
Da Nang 17
Des Moines 17
Redmond 17
Warsaw 17
Amsterdam 16
Hebei 16
Jakarta 16
Lappeenranta 16
Shanghai 16
Toronto 16
Saint Petersburg 15
Falkenstein 14
Orem 14
Turku 14
Casalecchio di Reno 13
Changsha 13
Bremen 12
Brussels 12
Denver 12
Mexico City 12
Paris 12
Quận Bình Thạnh 12
Tongling 12
Chennai 11
Haiphong 11
Hangzhou 11
Medford 11
Modena 11
Phoenix 11
Abeokuta 10
Faenza 10
Hyderabad 10
Naples 10
Ningbo 10
Quận Bảy 10
Verona 10
Biên Hòa 9
Fremont 9
Guayaquil 9
Haikou 9
Hải Dương 9
Montreal 9
Totale 7.291
Salva come PNG Salva come JPEG
Nome #
Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study 388
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 381
OS-077 Single-cell RNA sequencing of peripheral blood mononuclear cells in patients with acutely decompensated cirrhosis reveals a specific monocyte subset associated with an increased risk of progression to ACLF 310
Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study 290
Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients 230
Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment 226
Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids 210
Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register 203
A case of pneumonia and sepsis in cirrhosis as paradigm of the problems in the management of bacterial infections in cirrhosis and of the limitations of current knowledge 202
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial 197
Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF 181
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications 178
Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register 176
Mortality rate and risk factors for gastrointestinal bleeding in elderly patients 172
Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure 168
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 165
Acute-on-chronic liver failure is a distinct syndrome developing in patients with acute dcompensation of cirrhosis. 164
A case of prolonged cholestatic hepatitis induced by azithromycin in a young woman 163
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites 162
Real-word experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-Answer study) 161
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial 161
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis 160
Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. 160
Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register 160
The analysis of food intake in patients with cirrhosis waiting for liver transplantation: A neglected step in the nutritional assessment 160
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 160
How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. 156
A Case of Immune-Mediated Liver Injury Induced by Olaparib 152
QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? 150
Low haemoglobin level predicts early hospital readmission in patients with cirrhosis and acute decompensation 147
Role of human albumin in the management of complications of liver cirrhosis. 147
The Role of Transjugular Intrahepatic Portosystemic Shunt for the Management of Ascites in Patients with Decompensated Cirrhosis 145
Disorders of albumin metabolism in liver diseases. 144
Human albumin in the management of complications of liver cirrhosis. 138
null 138
Development and validation of a prognostic score to predict mortality in patients with acute on chronic liver failure. 134
Assessing the role of amino acids in systemic inflammation and organ failure in patients with {ACLF} 134
Incidence and clinical implications of abstinence-induced hepatic recompensation in decompensated alcohol-related cirrhosis 132
Albumin administration in internal medicine: A journey between effectiveness and futility 131
Hyposplenism as a cause of pneumococcal meningoencephalitis in an adult patient with coeliac disease 129
A web-based group treatment for patients with alcoholic liver diseases at the time of the COVID-19 pandemic 128
Human albumin in the management of complications of cirrhosis. 127
Predictors of clinical trajectories of patients with acutely decompensated cirrhosis. An external validation of the PREDICT study 124
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis 120
Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation 120
Reversal of liver fibrosis by the antagonism of endocannabinoid CB1-receptor in a rat model of CCl4-induced advanced cirrhosis. 118
Approach and management of dysnatremias in cirrhosis 118
Albumin: Indications in chronic liver disease 115
Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature 114
Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET) 113
Patients with cirrhosis and ascites treated with long-term albumin: An integrated management proposal based on a real-life study 113
Pro: The Role of Albumin in Pre–Liver Transplant Management 111
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology 111
Prolonged albumin administration in patients with decompensated cirrhosis: the amount makes the difference 108
Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant 107
Predictors of clinical trajectories in patients admitted for acutely decompensated cirrhosis: An external validation of the PREDICT study 105
Outcomes of patients with alcohol-related cirrhosis referred to a hepatology outpatient clinic 105
Real-world experience with long-term albumin in patients with cirrhosis and ascites 104
Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis 103
Management of ascites in patients with cirrhosis: An update 99
Simvastatin plus Rifaximin to prevent ACLF in patients with decompensated cirrhosis. A randomised, double-blind, placebo-controlled, phase-3 trial: the liverhope efficacy trial 98
Pattern of in-hospital changes in drug use in the older people from 2010 to 2016 97
Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease 97
Clinical trajectories of patients with cirrhosis and ascites receiving long-term albumin. A proposal for a personalized management based on real-world experience 96
Management of cirrhotic patients with ascites. 94
The Use of Rifaximin in Patients With Cirrhosis 94
Statins, ACE/ARBs drug use, and risk of pneumonia in hospitalized older patients: a retrospective cohort study 92
Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects 92
Defining aging phenotypes and related outcomes: Clues to recognize frailty in hospitalized older patients 90
Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis 89
null 88
Living alone as an independent predictor of prolonged length of hospital stay and non-home discharge in older patients 87
Correction and Prevention of Hyponatremia in Patients With Cirrhosis and Ascites: Post Hoc Analysis of the ANSWER Study Database 86
Predictors of clinical courses in patients wih acutely decompensated cirrhosis. An external validation of the PREDICT study 86
Need for deprescribing in hospital elderly patients discharged with a limited life expectancy: The REPOSI study 84
Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium 83
Long‐term albumin improves the outcomes of patients with decompensated cirrhosis and diabetes mellitus: Post hoc analysis of the ANSWER trial 79
Prognostic value of degree and types of anaemia on clinical outcomes for hospitalised older patients 78
Prevention of cirrhosis complications: Looking for potential disease modifying agents 74
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis 73
Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial 70
Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. 67
Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis 65
Managing Multiorgan Failure in Acute on Chronic Liver Failure 63
Albumin in hospitalized patients with complications of cirrhosis: Not a suit for all seasons 62
null 59
The role and indications of albumin in advanced liver disease 56
Correction to ‘Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF’ [J Hepatol 2020 (72) 688–701] (Journal of Hepatology (2020) 72(4) (688–701), (S0168827819306968), (10.1016/j.jhep.2019.11.009)) 36
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 32
Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease 25
null 3
null 3
null 1
Totale 11.827
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.598
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.598
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021849 0 0 0 0 0 0 37 78 104 37 55 538
2021/20221.390 157 27 63 84 118 80 35 142 56 74 403 151
2022/20231.415 111 220 77 140 94 114 42 91 235 44 120 127
2023/2024679 32 72 53 80 38 132 31 45 19 36 95 46
2024/20252.460 107 358 207 203 316 138 122 95 96 209 168 441
2025/20263.534 762 611 575 558 607 335 86 0 0 0 0 0
Totale 11.827